Incyte

5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Incyte
graft vs host disease
Novartis
Jakafi
Flag link:
Agenus sells cut of Incyte, Merck milestone streams
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Agenus
Incyte
Merck
Xoma
Flag link:
Incyte preps Jakafi expansion into graft-versus-host disease
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Incyte
Jakafi
graft vs host disease
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
3 Biotechs With Huge FDA Decisions in June
3 Biotechs With Huge FDA Decisions in June
Motley Fool
biotech
Array Biopharma
encorafenib
binimetinib
GW Pharma
Epidiolex
Incyte
olumiant
Flag link:
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
ASCO
oncology
IDO inhibitors
Incyte
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination
Fierce Biotech
Incyte
epacadostat
Keytruda
IDO inhibitors
Flag link:
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
[video]Why One Drug Flop Tanked Incyte's Stock
[video]Why One Drug Flop Tanked Incyte's Stock
Motley Fool
Incyte
epacadostat
Flag link:
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Motley Fool
Incyte
Merck
epacadostat
IDO inhibitors
Roche
NewLink Genetics
Flag link:
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
Motley Fool
Nektar Therapeutics
Incyte
Merck
NKTR-214
Bristol-Myers Squibb
Flag link:
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Incyte
Merck
melanoma
epacadostat
Keytruda
clinical trials
metastatic melanoma
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
Incyte study could bring lessons for cancer immunotherapy
Incyte study could bring lessons for cancer immunotherapy
Biopharma Dive
Incyte
cancer immunotherapy
metastatic melanoma
Merck
Keytruda
Flag link:
Concert rethinks R&D plans after loss in Incyte patent case
Concert rethinks R&D plans after loss in Incyte patent case
Fierce Biotech
Concert Pharmaceuticals
Incyte
patents
R&D
CTP-543
Flag link:

Pages